Salud financiera de hoja de balance de Ampio Pharmaceuticals

Salud financiera controles de criterios 4/6

Ampio Pharmaceuticals tiene un patrimonio de los accionistas total de $5.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $7.6M y $2.3M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$6.43m
Patrimonio	US$5.38m
Total pasivo	US$2.27m
Activos totales	US$7.65m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($7.6M) de APH superan a sus pasivos a corto plazo ($2.3M).

Pasivo a largo plazo: APH no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: APH está libre de deudas.

Reducción de la deuda: APH no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: APH tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: APH tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.1% cada año

Salud financiera de hoja de balance de Ampio Pharmaceuticals

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Recent updates

Ampio Announces Voluntary Delisting and SEC Deregistration

Ampio Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3159 million.

Ampio Pharmaceuticals, Inc. Provides Litigation Update

Ampio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10.4375 million.

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy .

Ampio Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Levi & Korsinsky Notifies Ampio Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NYSE to Commence Delisting Procedure for Ampio Pharmaceuticals' Common Stock

Glancy Prongay & Murray LLP Files A Class Action Lawsuit Against Ampio Pharmaceuticals, Inc

Robbins LLP Files A Securities Fraud Lawsuit Against Ampio Pharmaceuticals, Inc

Ampio Pharmaceuticals, Inc., Annual General Meeting, Aug 10, 2022

Ampio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Less than half of directors are independent

Ampio Pharmaceuticals, Inc. Announces Executive Changes

Ampio Provides Regulatory Update

Ampio Pharmaceuticals Releases Positive Phase 3 Data Analysis for Ampion Targeting Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals Appoints Elizabeth Varki Jobes as Member of the Board and as Member of the Nominating and Corporate Governance Committee of the Board

Less than half of directors are independent

Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India

Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress

Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program

Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Ampio Pharmaceuticals, Inc. Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial

Ampio Pharmaceuticals, Inc. Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Ampio Pharmaceuticals Reveals Early Positive Results for Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals, Inc. Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Ampio Pharmaceuticals, Inc. Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in Covid-19 Respiratory Distress

Ampio Pharmaceuticals Provides Update on Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of Covid-19 Patients

Ampio Pharmaceuticals, Inc. Receives Feedback from the FDA on Ampio’s Proposed Modifications to the Special Protocol Asssessment for Ampion Treatment of Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals, Inc. Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion

Ampio Pharmaceuticals, Inc. Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

New 90-day high: €0.98

Ampio Pharmaceuticals, Inc. Announces the AP-014 Phase I Inhaled Ampion™ Clinical Study In COVID-19 Patients

Ampio Pharmaceuticals, Inc. Announces its Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Begins Phase 1 Clinical Trial of Inhaled Ampion for Covid-19 Patients with Respiratory Distress

Ampio Pharmaceuticals, Inc. Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

Ampio Pharmaceuticals, Inc. Announces the Receipt of an Investigational New Drug from the U.S. Food and Drug Administration

New 90-day high - €0.69

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera